Skip to content
Screener

10x Genomics, Inc. TXG Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Bruker logo
BrukerBRKR
$623.1M+18.1%
Azenta logo
AzentaAZTA
$277.52M
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
$408.46M+1.0%
Illumina logo
IlluminaILMN
Agilent Technologies logo
Agilent TechnologiesA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$151.0M-12.6%
Gross profit$112.5M-10.1%
Operating income-$19.6M-165%
Net income-$17.9M-152%
EPS (diluted)-$0.14-150%

Balance sheet

See full
Cash & equivalents$502.5M+26.4%
Total debt$78.8M-9.2%
Total equity$825.5M+6.8%
Total assets$1.0B+5.1%

Cash flow

See full
Operating cash flow$17.0M-4.1%
CapEx$1.6M+0.6%
Free cash flow$15.4M-4.6%

Valuation

See full
Market cap$6.61B+331%
Enterprise value$6.18B+406%
P/S10.7×+8.3×

Profitability

See full
Gross margin70%+0.5pp
Operating margin-14.3%-1.1pp
Net margin-12.2%-0.8pp
FCF margin19.7%+10.9pp

Returns & leverage

See full
Return on equity-9.4%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.7×-0.1×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054491
Line itemJune 30, 2026 / Remaining Useful Life in YearsJune 30, 2026 / Gross Carrying AmountJune 30, 2026 / Accumulated AmortizationJune 30, 2026 / Intangibles,NetDecember 31, 2025 / Gross Carrying AmountDecember 31, 2025 / Accumulated AmortizationDecember 31, 2025 / Intangibles,Net
Developed technology5.8$56,338$(7,458)$48,880$52,639$(3,359)$49,280
Technology licenses8.322,504(10,226)12,27822,504(9,491)13,013
Assembled workforce01,328(1,326)21,328(1,292)36
Customer Relationships0945(945)945(945)
Total intangible assets, net$81,115$(19,955)$61,160$77,416$(15,087)$62,329

Item 1. Financial Statements (Unaudited)

FAQ

What is 10x Genomics, Inc.'s finite-lived intangible assets, accumulated amortization?
10x Genomics, Inc. (TXG) reported finite-lived intangible assets, accumulated amortization of $19.96M in Q2 2026.
What is the long-term trend for 10x Genomics, Inc.'s finite-lived intangible assets, accumulated amortization?
Over 2 years (2020 to 2025), 10x Genomics, Inc.'s finite-lived intangible assets, accumulated amortization has grown at a 156.8% compound annual growth rate (CAGR), from $2.29M to $15.09M.
What does finite-lived intangible assets, accumulated amortization mean?
Finite-Lived Intangible Assets, Accumulated Amortization

Ask your AI about 10x Genomics, Inc.'s finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude